These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 6431147

  • 1. [Chronic liver dysfunction in patients with hemophilia A. Effect of introduction of factor VIII concentrate].
    Kojima S, Tonouchi T, Ikegaya M, Mimaya J.
    Rinsho Ketsueki; 1984 Jan; 25(1):31-6. PubMed ID: 6431147
    [No Abstract] [Full Text] [Related]

  • 2. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran).
    Mansour-Ghanaei F, Fallah MS, Shafaghi A, Yousefi-Mashhoor M, Ramezani N, Farzaneh F, Nassiri R.
    Med Sci Monit; 2002 Dec; 8(12):CR797-800. PubMed ID: 12503038
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of type B and non-A, non-B hepatitis in hemophilia: relationship to chronic liver disease.
    Kim HC, Saidi P, Ackley AM, Bringelsen KA, Gocke DJ.
    Gastroenterology; 1980 Dec; 79(6):1159-64. PubMed ID: 6777232
    [Abstract] [Full Text] [Related]

  • 4. Incidence and course of inhibitors among patients with classic hemophilia.
    Kasper CK.
    Thromb Diath Haemorrh; 1973 Nov; 30(2):263-71. PubMed ID: 4773365
    [No Abstract] [Full Text] [Related]

  • 5. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
    Lange D, Lazerson J.
    Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
    [No Abstract] [Full Text] [Related]

  • 6. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J, Skulimowska J, Windyga J, Lopaciuk S, Kościelak J.
    Arch Immunol Ther Exp (Warsz); 2005 Feb; 53(4):352-6. PubMed ID: 16088320
    [Abstract] [Full Text] [Related]

  • 7. An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as the source.
    Kedda MA, Kew MC, Cohn RJ, Field SP, Schwyzer R, Song E, Fernandes-Costa F.
    Hepatology; 1995 Nov; 22(5):1363-7. PubMed ID: 7590648
    [Abstract] [Full Text] [Related]

  • 8. Prophylaxis in haemophilic children.
    Liesner RJ.
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [Abstract] [Full Text] [Related]

  • 9. Coagulation factor therapy for hemophilia: relation to hepatitis B and to liver function.
    Card RT, Dusevic M, Lukie BE.
    Can Med Assoc J; 1982 Jan 01; 126(1):34-6. PubMed ID: 7059871
    [Abstract] [Full Text] [Related]

  • 10. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R, Quintana Gonzalez S, Martinez Murillo C, Dominguez Garcia V, Rodriguez Moyado H, Collazo Jaloma J.
    Arch Med Res; 1996 Jan 01; 27(1):15-8. PubMed ID: 8867361
    [Abstract] [Full Text] [Related]

  • 11. Fifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrate.
    Mäkipernaa A, von Bonsdorff L.
    Haemophilia; 2008 May 01; 14(3):612-4. PubMed ID: 18312362
    [No Abstract] [Full Text] [Related]

  • 12. Virology of the hepatitis A epidemic in Italy.
    Purcell RH, Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, Ciavarella N, Emerson SU.
    Vox Sang; 1994 May 01; 67 Suppl 4():2-7; discussion 24-6. PubMed ID: 7831866
    [Abstract] [Full Text] [Related]

  • 13. Hepatitis A among persons with hemophilia who received clotting factor concentrate--United States, September-December 1995.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 1996 Jan 19; 45(2):29-32. PubMed ID: 8531917
    [Abstract] [Full Text] [Related]

  • 14. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
    Guérois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos AM, Négrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M.
    Thromb Haemost; 1995 Feb 19; 73(2):215-8. PubMed ID: 7792732
    [Abstract] [Full Text] [Related]

  • 15. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.
    Berntorp E, Astermark J, Carlborg E.
    Haematologica; 2000 Oct 19; 85(10 Suppl):48-50; discussion 50-1. PubMed ID: 11187871
    [Abstract] [Full Text] [Related]

  • 16. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A.
    Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briët E, van den Berg HM.
    Thromb Haemost; 1994 Jun 19; 71(6):703-6. PubMed ID: 7974335
    [Abstract] [Full Text] [Related]

  • 17. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.
    Sabin C, Pasi J, Phillips A, Elford J, Janossy G, Lee C.
    Thromb Haemost; 1994 Aug 19; 72(2):214-7. PubMed ID: 7831654
    [Abstract] [Full Text] [Related]

  • 18. [Perioperative management of orthopaedic patients with hemophilia A].
    Wu YG, Li XG, Zhang KN, Ren YJ, Li SF, Lu MY.
    Zhonghua Wai Ke Za Zhi; 2004 Dec 07; 42(23):1430-3. PubMed ID: 15733456
    [Abstract] [Full Text] [Related]

  • 19. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC, Greenwood R, Escobar M, Frelinger JA.
    Haematologica; 2000 Oct 07; 85(10 Suppl):113-6. PubMed ID: 11187862
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.